Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2017

01-04-2017 | Gastrointestinal Oncology

Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution’s Experience During Two Decades

Authors: Chukwuemeka Ihemelandu, MD, FACS, Paul H. Sugarbaker, MD, FACS, FRCS

Published in: Annals of Surgical Oncology | Issue 4/2017

Login to get access

Abstract

Background

Peritoneal metastasis of colonic origin is associated with a poor prognosis. This study aimed to analyze the clinicopathologic characteristics and prognostic predictors of survival in a cohort of patients treated with cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (POIC) during two decades.

Methods

A retrospective study analyzed a prospectively maintained database for all patients treated for peritoneal metastasis of a colonic origin (PCC) from January 1990 to April 2015.

Results

The 318 patients in our study comprised 171 men (53.8%) and 147 women (46.2%). The mean age of the patients at presentation was 50.6 years, (range 18–86 years). Overall survival was 42.5%, median survival and follow-up time was 21.5 and 15.0 months respectively. The 3 and 5 years survival rates were respectively 35 and 25%. The median survival time was 20.6 months for the men and 23.1 months for the women (p = 0.14). The mean intraoperative peritoneal carcinomatosis index (PCI) was 15.2. The patients who had a completeness of cytoreduction (CC) score of 0 or 1 (no residual disease <0.25 mm) had a median survival time of 36.6 months compared with 18.3 months for the patients with a CC-2 score and 7.6 months for the patients with a CC-3 score (p < 0.000). The significant independent predictors of survival in the multivariate analysis were the CC score and elevated tumor makers CA153 and CA125.

Conclusion

For patients with a limited extent of peritoneal metastases, CC is the most important prognostic variable for improved survival of colon cancer patients with peritoneal metastases.
Literature
1.
Howlader N, Noone AM, Krapcho M, et al (eds). SEER cancer statistics review, 1975–2010. National Cancer Institute, Bethesda 2013.
2.
Minsky BD, Mies C, Rich TA, et al. Potentially curative surgery of colon cancer: patterns of failure and survival. J Clin Oncol. 1988;6:106–18.CrossRefPubMed
3.
Russell AH, Tong D, Dawson LE, et al. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys. 1983;9:361–5.CrossRefPubMed
4.
Jayne Fook DGS, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.CrossRefPubMed
5.
Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.CrossRefPubMed
6.
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–18.CrossRefPubMed
7.
Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015;96,156–66.CrossRefPubMed
8.
Franko J, Shi Q, Goldman CD, Pockage B, Nelson B, Goldberg R, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.CrossRefPubMed
9.
Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38, 617–23.CrossRefPubMed
10.
Sugarbaker PH. An overview of peritonectomy, visceral resections, and perioperative chemotherapy for peritoneal surface malignancy. In: Sugarbaker PH (ed) Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy (textbook and video atlas). Cine-Med Publishing, Woodbury, CT, 2012, pp 1–30.
11.
12.
Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal metastasis. J Exp Clin Cancer Res. 1996;15:49–58.
13.
Mohamed F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin North Am. 2003;12:825–33.CrossRef
14.
Sugarbaker PH. An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol. 2005;92:142–6.CrossRefPubMed
15.
Elias D, Mariani A, Cloutier AS, Blot F, Goéré D, Dumont F, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2014a;40:1467–73.CrossRefPubMed
16.
Benizri EI, Bernard JL, Rahili A, Benchimol D, Bereder JM. Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2012;10:56.CrossRefPubMedPubMedCentral
17.
Blackham AU, Russell GB, Stewart JH IV, Votanopoulos K, Levine EA, Shen P. Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21:2667–74.CrossRefPubMedPubMedCentral
18.
Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J. 2013;2013:978394.CrossRef
19.
Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Masvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.CrossRefPubMed
20.
Froysnes I, Larsen S, Spasojevic M, et al. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016. DOI:10.​1002/​jso.​24290.PubMed
21.
Baratti D, Kusamura S, Pietrantonio F, et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015: a systematic review. Crit Rev Oncol Hematol. 2016;100:209–22.CrossRefPubMed
22.
Faron M, Macovei R, Goere D, et al. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23:114–9.CrossRefPubMed
Metadata
Title
Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution’s Experience During Two Decades
Authors
Chukwuemeka Ihemelandu, MD, FACS
Paul H. Sugarbaker, MD, FACS, FRCS
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5698-x

Other articles of this Issue 4/2017

Annals of Surgical Oncology 4/2017 Go to the issue

Thoracic Oncology

Long-Term Impact of Postoperative Complications on Cancer Recurrence Following Lung Cancer Surgery

Gastrointestinal Oncology

Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer

Gastrointestinal Oncology

Inflammation-Based Prognostic Scores: Utility in Prognostication and Patient Selection for Cytoreduction and Perioperative Intraperitoneal Chemotherapy in Patients with Peritoneal Metastasis of Colonic Origin

Gastrointestinal Oncology

Ultimate Clinical Outcomes of Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential

Gastrointestinal Oncology

Reliable Surgical Techniques for Lymphadenectomy Along the Left Recurrent Laryngeal Nerve During Thoracoscopic Esophagectomy in the Prone Position

Colorectal Cancer

A Postoperative Systemic Inflammation Score Predicts Short- and Long-Term Outcomes in Patients Undergoing Surgery for Colorectal Cancer